Sanofi Licenses an AI Scientist. Collate Hits $1 Billion on Regulatory Docs. The Governance Gap Is Becoming a Product.
Last week we tracked Veeva shipping its agentic architecture and pharma building AI it owns. This week, the deal flow moved further down the stack. Sanofi signed a five-year agreement with Owkin to deploy K Pro, an AI scientist agent, across biopharma development workflows. Collate raised $95 million and crossed a near-billion dollar valuation by cutting regulatory document processing time by up to 90%. Agilent partnered with OpenAI and BCG to embed AI across its instruments, operations, and customer workflows. And Microsoft announced a partnership with Mayo Clinic to build a frontier AI model for healthcare — trained on Mayo's longitudinal clinical data and owned by the clinic, not by Microsoft. Underneath all of it, two stories signal where the industry is heading next: the FDA is now sending deficiency letters over AI explainability, not just performance, and a new analysis shows that AI governance in biotech CMC is fragmented and largely ungoverned.
